Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

Abstract

Administered at its MTD in mice, bortezomib demonstrated activity against selected lines of the PPTP's ALL in vivo panel. Further studies are indicated to determine the activity of bortezomib when combined with standard agents to treat childhood ALL.